MediPharm Labs Enters French Medicinal Cannabis Market with First Shipment

The latest update is out from MediPharm Labs ( (TSE:LABS) ).

MediPharm Labs has completed its first shipment to France, marking a significant milestone in its expansion into the European medicinal cannabis market. This achievement highlights the company’s capability to meet stringent European standards and strengthens its position as a trusted supplier of pharmaceutical-grade cannabis products. The French market is expected to grow significantly, and MediPharm’s strategic partnerships and global distribution network position it well to capitalize on this growth. As of Q3 2025, international medical cannabis accounted for 56% of the company’s revenue, demonstrating its successful global expansion.

Spark’s Take on TSE:LABS Stock

According to Spark, TipRanks’ AI Analyst, TSE:LABS is a Neutral.

MediPharm Labs faces significant challenges with profitability and cash flow, as reflected in its financial performance score. Technical indicators suggest bearish momentum, and the negative P/E ratio highlights valuation concerns. These factors collectively result in a low overall stock score.

To see Spark’s full report on TSE:LABS stock, click here.

More about MediPharm Labs

MediPharm Labs, founded in 2015, is a pharmaceutical company specializing in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products. The company operates a Good Manufacturing Practices certified facility and focuses on delivering precision-dosed cannabis products for domestic and international medical markets. MediPharm Labs holds a unique Pharmaceutical Drug Establishment License from Health Canada and has expanded its reach through strategic acquisitions and partnerships.

Average Trading Volume: 347,639

Technical Sentiment Signal: Sell

Current Market Cap: C$27.35M

For an in-depth examination of LABS stock, go to TipRanks’ Overview page.